Application of transurethral blue laser vaporization of the prostate in Patients Aged 80 and Above: A Single-Center Clinical Analysis of 157 Cases

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Purpose: This study aims to assess the safety and effectiveness of transurethral blue laser prostate vaporization (BVP) for elderly patients (≥80 years) with benign prostatic hyperplasia (BPH), focusing on clinical outcomes, recovery, and complications. Methods: A retrospective analysis was performed on 157 BPH patients aged ≥80 years who underwent BVP at a single center between May 2023 and May 2025. Data on demographics, prostate volume, comorbidities, procedure details, and postoperative outcomes were collected. Results: The mean age was 83.97±3.63 years, with an average prostate volume of 63.34±34.95 ml. Patients had an average of 2.5 comorbidities, and 26.1% required additional surgical interventions. The average procedure time was 28.2±12.1 minutes, with a median hospital stay of 9 days. Postoperative IPSS scores decreased significantly to 4.3±3.5. Mild red blood cell loss (hemoglobin decreased by 6.1%, p<0.001) and a significant inflammatory response (neutrophils increased by 26.5%, p<0.001) were observed, but no transfusion was needed. Conclusion: Transurethral blue laser prostate vaporization is a safe and effective option for elderly BPH patients with multiple comorbidities, offering significant symptom improvement with minimal postoperative complications.

Article activity feed